Neuromodulation Devices
•17 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (17)
%
| Company | Market Cap | Price |
|---|---|---|
|
Delivers neuromodulation/nerve ablation devices (Intracept), plus ultrasound-based renal denervation platforms.
|
$141.15B |
$95.41
-1.94%
|
|
Neuromodulation Devices - pain management and neuromodulation/ablation technologies (e.g., OptaBlate BVN).
|
$139.34B |
$364.60
-1.54%
|
|
Neuromodulation Devices (e.g., Inceptiv closed-loop SCS, Percept DBS) constitute MDT's specialized neural therapy products for movement disorders and other neuromodulation indications.
|
$122.30B |
$95.45
-1.27%
|
|
Targets neuromodulation devices as a high-growth market for its manufacturing services.
|
$3.53B |
$101.05
-1.93%
|
|
Directly manufactures and sells neuromodulation devices including VNS Therapy for epilepsy and proximal HGNS for OSA.
|
$2.76B |
$50.69
-2.14%
|
|
Inspire Medical Systems' flagship product is a neuromodulation device (Inspire V) delivering hypoglossal nerve stimulation for OSA.
|
$2.22B |
$75.17
-6.27%
|
|
Avanos' three-tiered RFA portfolio positions the company in Neuromodulation Devices.
|
$494.81M |
$10.70
-4.63%
|
|
Core product is a brain-responsive neuromodulation device (RNS System) used for drug-resistant epilepsy.
|
$337.17M |
$10.28
-5.34%
|
|
CVRx directly manufactures and sells Barostim, an implantable neuromodulation device for heart failure, fitting Neuromodulation Devices.
|
$210.41M |
$7.88
+0.51%
|
|
NeuroStar Advanced Therapy System is a neuromodulation medical device, representing the core product Neuronetics sells.
|
$183.64M |
$2.79
-5.10%
|
|
The platform enables brain stimulation and nerve ablation therapies, aligning with neuromodulation devices.
|
$47.33M |
$0.95
-7.77%
|
|
Core non-invasive neuromodulation devices (gammaCore, Quell, Sparrow Ascent, TAC-STIM) are the company's direct product offerings.
|
$37.10M |
$5.00
-5.12%
|
|
IB-Stim and RED represent neuromodulation-related medical devices, a core device category the company directly designs/manufactures.
|
$22.95M |
$3.18
-1.24%
|
|
Cochlear implants deliver electrical stimulation to neural tissue (auditory nerve), aligning with the neuromodulation device category.
|
$18.87M |
$0.89
-8.29%
|
|
MyoCycle FES cycles involve functional electrical stimulation therapy devices, a neuromodulation-related product in Lifeward's portfolio.
|
$8.79M |
$0.80
-5.39%
|
|
Energy delivery to peripheral nerves to modulate neural activity aligns with neuromodulation device applications.
|
$3.39M |
$1.26
-5.97%
|
|
PoNS is a non-invasive neuromodulation device used to treat gait and balance deficits.
|
$155247 |
$14.70
-10.80%
|
Loading industry metrics...
Loading comparison data...
